Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)-Reference-Cited by-同舟云学术

Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)

Published:2024-08-07 Issue:8 Volume:68 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ponta Giacomo¹²^ORCID,Morena Valentina¹,Strano Martina¹²,Molteni Chiara¹,Pontiggia Silvia¹^ORCID,Cavalli Erica Michela³,Grancini Anna⁴,Mauri Carola⁵,Castagna Antonella²,Galanti Andrea⁶,Piconi Stefania¹^ORCID

Affiliation:

1. Infectious Diseases Unit, Ospedale A. Manzoni ASST-Lecco, Lecco, Italy

2. Infectious Diseases Unit, Università Vita-Salute S. Raffaele, Milano, Italy

3. Plastic and Hand Surgery Department, IRCCS San Gerardo, Monza, Italy

4. Microbiology and Virology Unit Fondazione IRCCS Cà Granda O. Maggiore Policlinico, Milan, Italy

5. Microbiology and Virology Unit, A. Manzoni ASST-Lecco, Lecco, Italy

6. Cardiac Surgery Unit, A. Manzoni ASST-Lecco, Lecco, Italy

Abstract

ABSTRACT Rezafungin is an echinocandin characterized by a long elimination half-life which allows for weekly administration. It has been recently approved for the treatment of candidemia. Few data are available about the long-term use of rezafungin and its use for deep infections like endocarditis and osteomyelitis. We describe our experience with its prolonged use in two azole-resistant Candida infections: a case of sacral osteomyelitis and a prosthetic valve endocarditis also involving a thoracic endovascular aneurysm repair.

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00750-24

Reference19 articles.

1. The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective

2. Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches

3. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial

4. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

5. Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case Commentary: Extending our therapeutic range against multidrug-resistant Candida;Antimicrobial Agents and Chemotherapy;2024-08-07